were analyzed by encounter (in-person vs telemedicine [TMed]), clinic and provider type. We also interviewed 16 providers about perceived COVID-19 impact on pediatric ambulatory antibiotic prescribing. Student's T and $\chi^2$ tests were used as appropriate.

**Results.** The number of pediatric ambulatory visits was 16671 in P1 and 7010 in P2. There were no TMed visits in P1 vs 188 in P2 (2.7% of total P2 visits); 186 (99% of TMed visits) were in PCC (Table). In all settings, the number of encounters was lower in P2 vs P1 (p < 0.001). The percent of encounters with an antibiotic prescription was lower in P2 (32%) than in P1 (38.2%) (p < 0.001) (Table) overall and in all settings except RHCs. Only 14 (7.4%) TMed visits resulted in an antibiotic prescription. There were no differences in antibiotic prescribing rates by provider type. Diagnoses varied significantly between periods in all clinic types except the ED, with noninfectious diagnoses being higher in P2 vs P1 (Figure 1). Providers felt that COVID-19 led to fewer sicker patients presenting for care, and variable impact on antibiotic prescribing (Figure 2).

Table. Percent of Encounters with an Antibiotic by Clinic Type, Pre- and Post-COVID-19

| Location and Provider Type | Pre-COVID-19 | Post-COVID-19 | p-value* |
|---------------------------|--------------|---------------|---------|
| Emergency Department (111 visits) | 12 NP | 12A | 74 trained |
| Pediatric inpatient (18 visits) | 37 | 42 | 122 trained |
| Pediatric ICU (12 visits) | 4 | 28 | 205 trained |
| Pediatric Consultation (2 visits) | 10 | 14 | 28 trained |

Figure 1. Diagnosis Rates by Clinic Type, Pre- and Post-COVID-19

**Conclusion.** The proportion of encounters with non-infectious diagnoses increased and antibiotic prescribing rates decreased significantly in all pediatric ambulatory settings post-COVID-19 except RHCs. Almost all TMed encounters occurred in the primary care setting, and few resulted in an antibiotic prescription. Providers felt they saw fewer patients and higher acuity of illness post COVID-19.

**Disclosures.** Hillary Spencer, MD, MPH, NIH (T32 grant support) (Grant/Research Support)

1346. Implementation of a Multidisciplinary 48 Hour Antibiotic Timeout in a Pediatric Population

Victoria Konold, MD; Palak Bhagat, PharmD, BCPS; Jennifer Pisano, MD; Natasha N. Pettit, PharmD; Anish Choksi, PharmD; Cynthia Nguyen, PharmD; Madan Kumar, DO; University of Chicago, Western Springs, Illinois; University of Chicago Medicine, Chicago, IL.

**Session.** P-60. Pediatric Antimicrobial Stewardship (inpatient/outpatient pediatric focused)

**Background.** To meet the core elements required for antimicrobial stewardship programs, our institution implemented a pharmacy-led antibiotic timeout (ATO) process in 2017 and a multidisciplinary ATO process in 2019. An antibiotic timeout is a discussion and review of the need for ongoing empirical antibiotics 2-4 days after initiation. This study sought to evaluate both the multidisciplinary ATO and the pharmacy-led ATO in a pediatric population, compare the impact of each intervention on antibiotic days of therapy (DOT) to a pre-intervention group without an ATO, and to then compare the impact of the pharmacy-led ATO versus multidisciplinary ATO on antibiotic days of therapy (DOT).

**Methods.** This was a retrospective, pre-post, quasi-experimental study of pediatric patients comparing antibiotic DOT prior to ATO implementation (pre-ATO), during the pharmacy-led ATO (pharm-ATO), and during the multidisciplinary ATO (multi-ATO). The pre-ATO group was a patient sample from February-September 2016, prior to the initiation of a formal ATO. The pharmacy-led ATO was implemented from February-September 2018. This was followed by a multidisciplinary ATO led by pediatric residents and nurses from February-September 2019. Both the pharm-ATO and the multi-ATO were implemented as an active non-interruptive alert added to the electronic health record patient list. This alert triggered when new antibiotics had been administered to the patient for 48 hours, at which time, the responsible clinician would discuss the antibiotic and document their decision via the alert workspace. Pediatric inpatients receiving IV or PO antibiotics administered for at least 48 hours were included. The primary outcome was DOT. Secondary outcomes included length of stay (LOS) and mortality.

**Results.** 1284 unique antibiotic orders (n=572 patients) were reviewed in the pre-ATO group, 886 (n=323 patients) in the pharm-ATO and 949 (n=305 patients) in the multi-ATO groups. Average DOT was not significantly different pre vs post intervention for either methodology (Table 1). Mortality was similar between groups, but LOS was longer for both intervention groups (Table 1).

**Impact of an ATO on DOT, Mortality and LOS**

**Conclusion.** An ATO had no impact on average antibiotic DOT in a pediatric population, regardless of the ATO methodology.

**Disclosures.** All Authors: No reported disclosures

1347. Improved Antibiotic Prescribing Practices for Respiratory Infections Through Use of Computerized Order Sets and Educational Sessions in Pediatric Clinics

Yorge Zahlanie, MD; Norman Mang, PharmD, BCIDP; Kevin Lin, PharmD; Linda S. Hyman, PhD; Bonnie C. Prokesch, MD; University of Texas Southwestern Medical Center, Dallas, Texas; Parkland Health & Hospital System, Dallas, TX; Parkland Hospital, Dallas, TX

**Session.** P-60. Pediatric Antimicrobial Stewardship (inpatient/outpatient pediatric focused)

**Background.** The literature about comprehensive outpatient antimicrobial stewardship programs remains sparse. However, computerized clinical decision support systems (CDSs) have shown promising effectiveness in improving outpatient antibiotic prescribing practices.

**Methods.** We developed an intervention in the form of EPIC order sets comprised of outpatient treatment pathways for 3 pediatric bacterial acute respiratory infections or ARIs (otitis media, community-acquired pneumonia, and streptococcal pharyngitis) coupled with educational sessions. Two study periods were included, and 4 pediatric clinics were randomized into intervention and control arms. Education was provided to the 2 intervention clinics during the pharmacy-led ATO (pharm-ATO) process in 2017 and a multidisciplinary ATO process in 2019. An antibiotic timeout is a discussion and review of the need for ongoing empirical antibiotics 2-4 days after initiation. This study sought to evaluate both the multidisciplinary ATO and the pharmacy-led ATO in a pediatric population, compare the impact of each intervention on antibiotic days of therapy (DOT) to a pre-intervention group without an ATO, and to then compare the impact of the pharmacy-led ATO versus multidisciplinary ATO on antibiotic days of therapy (DOT).

**Results.** A total of 2690 antibiotic prescriptions were written for bacterial ARIs. At pre-intervention, there was no difference between the study arms in terms of DOT (74.9% vs. 77.7%, P=0.211) and antibiotic duration (9.69 ±0.96 days vs. 9.63 ±1.07 days, P=0.999). Following the intervention, the intervention clinics had higher rate of first-line antibiotic prescribing (83.1% vs. 77.7%, P=0.024) and shorter antibiotic duration (9.28 ±1.56 days vs. 9.79 ±0.75 days, P<0.001) compared to the control clinics. The rate of modified antibiotics was small in all clinics (1.1-1.6%) and not different at post-intervention (P=0.852) and post-intervention (P=0.552).